PMID- 24049252
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20130919
LR  - 20211021
IS  - 0970-2113 (Print)
IS  - 0974-598X (Electronic)
IS  - 0970-2113 (Linking)
VI  - 30
IP  - 3
DP  - 2013 Jul
TI  - Outcomes of patients with unresected stage III and stage IV non-small cell lung 
      cancer: A single institution experience.
PG  - 187-92
LID - 10.4103/0970-2113.116250 [doi]
AB  - INTRODUCTION: To report on the demographic profile and survival outcomes of North 
      Indian population affected with stage III and stage IV non-small cell lung cancer 
      (NSCLC). MATERIALS AND METHODS: From November 2008 to January 2012, 138 
      consecutively diagnosed NSCLC patients were included in this study. The patient, 
      tumor and treatment related factors were analyzed. Median overall survival (OS), 
      Kaplan-Meier survival plots, t-test, Cox proportional hazards models were 
      generated by multivariate analysis [MVA]) and analyzed on SPSS software (version 
      19.0; SPSS, Inc., Chicago, IL). RESULTS: Median OS of stage III patients was 9.26 
      +/- 1.85 months and 2-year survival rate of 13% while stage IV patients had median 
      OS of 5 +/- 1.5 months with a 2-year survival rate of 8%. Cox regression modeling 
      for MVA demonstrated higher biologically equivalent dose (BED) (P = 0.01) in 
      stage III while in stage IV non-squamous histology (P = 0.01), administration of 
      chemotherapy (P = 0.02), partial responders to chemotherapy (P = 0.001), higher 
      BED (P = 0.02), and those with skeletal metastasis alone (P = 0.17) showed a 
      better OS. CONCLUSION: Our data showed that a higher BED is associated with 
      favorable outcomes, indicating a role of dose escalated radiation therapy to the 
      primary lesion in both stage III and essentially in stage IV NSCLC. Additionally, 
      optimal use of chemotherapy relates to better survival. The developing, resource 
      restrained nations need to follow an economically feasible multimodality 
      approach.
FAU - Tiwana, Manpreet Singh
AU  - Tiwana MS
AD  - Department of Radiation Oncology, STM Cancer Research Institute, Himalayan 
      Institute Hospital Trust, Dehradun, India.
FAU - Lee, Hsueh Ni
AU  - Lee HN
FAU - Saini, Sunil
AU  - Saini S
FAU - Verma, S K
AU  - Verma SK
FAU - Gupta, Meenu
AU  - Gupta M
FAU - Gupta, Madhur
AU  - Gupta M
FAU - Jain, Navneet
AU  - Jain N
FAU - Sindhwani, Girish
AU  - Sindhwani G
FAU - Rawat, Jagdish
AU  - Rawat J
FAU - Saini, Manju
AU  - Saini M
FAU - Chauhan, Neena
AU  - Chauhan N
FAU - Gaur, Dushyant
AU  - Gaur D
LA  - eng
PT  - Journal Article
PL  - India
TA  - Lung India
JT  - Lung India : official organ of Indian Chest Society
JID - 8405380
PMC - PMC3775197
OTO - NOTNLM
OT  - Biologically equivalent dose
OT  - chemotherapy
OT  - non-small cell lung cancer
OT  - overall survival
OT  - radiation therapy
COIS- Conflict of Interest: None declared.
EDAT- 2013/09/21 06:00
MHDA- 2013/09/21 06:01
PMCR- 2013/07/01
CRDT- 2013/09/20 06:00
PHST- 2013/09/20 06:00 [entrez]
PHST- 2013/09/21 06:00 [pubmed]
PHST- 2013/09/21 06:01 [medline]
PHST- 2013/07/01 00:00 [pmc-release]
AID - LI-30-187 [pii]
AID - 10.4103/0970-2113.116250 [doi]
PST - ppublish
SO  - Lung India. 2013 Jul;30(3):187-92. doi: 10.4103/0970-2113.116250.